Kenneth Bruce Christopher, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Critical Illness | 54 | 2023 | 2670 | 8.430 |
Why?
|
| Vitamin D Deficiency | 23 | 2021 | 1343 | 3.610 |
Why?
|
| Vitamin D | 23 | 2020 | 3223 | 3.100 |
Why?
|
| Intensive Care Units | 30 | 2022 | 3679 | 2.810 |
Why?
|
| Malnutrition | 9 | 2022 | 625 | 2.720 |
Why?
|
| Cholecalciferol | 7 | 2021 | 537 | 2.020 |
Why?
|
| Nutritional Status | 9 | 2022 | 1609 | 1.590 |
Why?
|
| Hospital Mortality | 16 | 2022 | 5317 | 1.510 |
Why?
|
| Metabolomics | 7 | 2023 | 1484 | 1.480 |
Why?
|
| Erythrocyte Indices | 5 | 2020 | 146 | 1.480 |
Why?
|
| Metabolome | 6 | 2023 | 895 | 1.460 |
Why?
|
| Parenteral Nutrition | 3 | 2023 | 650 | 1.410 |
Why?
|
| Acute Kidney Injury | 7 | 2018 | 1972 | 1.390 |
Why?
|
| Patient Discharge | 8 | 2022 | 3313 | 1.270 |
Why?
|
| Vascular Surgical Procedures | 4 | 2022 | 1475 | 1.230 |
Why?
|
| Vitamins | 5 | 2021 | 1622 | 1.120 |
Why?
|
| Critical Care | 15 | 2020 | 2647 | 1.030 |
Why?
|
| Boston | 20 | 2019 | 9313 | 1.010 |
Why?
|
| Sepsis | 10 | 2017 | 2593 | 0.940 |
Why?
|
| Survivors | 4 | 2017 | 2291 | 0.920 |
Why?
|
| Nutrition Assessment | 3 | 2022 | 723 | 0.880 |
Why?
|
| Surgical Procedures, Operative | 4 | 2020 | 1876 | 0.870 |
Why?
|
| Kynurenine | 1 | 2022 | 139 | 0.830 |
Why?
|
| End Stage Liver Disease | 2 | 2016 | 314 | 0.820 |
Why?
|
| Vascular Diseases | 2 | 2021 | 1161 | 0.800 |
Why?
|
| Protein-Energy Malnutrition | 1 | 2022 | 187 | 0.790 |
Why?
|
| Cross Infection | 3 | 2015 | 1416 | 0.760 |
Why?
|
| Hospitalization | 11 | 2017 | 10262 | 0.750 |
Why?
|
| Logistic Models | 18 | 2019 | 13408 | 0.710 |
Why?
|
| Basal Metabolism | 1 | 2021 | 168 | 0.710 |
Why?
|
| Enteral Nutrition | 3 | 2023 | 763 | 0.680 |
Why?
|
| Middle Aged | 62 | 2022 | 213383 | 0.640 |
Why?
|
| Odds Ratio | 12 | 2017 | 9849 | 0.600 |
Why?
|
| Smoke Inhalation Injury | 1 | 2017 | 49 | 0.590 |
Why?
|
| Aged | 48 | 2023 | 163280 | 0.580 |
Why?
|
| Emergencies | 3 | 2018 | 1170 | 0.580 |
Why?
|
| Erythroblasts | 1 | 2017 | 150 | 0.580 |
Why?
|
| Graft Rejection | 10 | 2022 | 4397 | 0.560 |
Why?
|
| Male | 73 | 2023 | 350118 | 0.550 |
Why?
|
| Hypernatremia | 1 | 2016 | 82 | 0.540 |
Why?
|
| Community-Acquired Infections | 3 | 2013 | 465 | 0.520 |
Why?
|
| Female | 66 | 2023 | 380194 | 0.510 |
Why?
|
| Liver Function Tests | 1 | 2016 | 528 | 0.490 |
Why?
|
| Eosinophils | 1 | 2019 | 955 | 0.480 |
Why?
|
| Risk Factors | 26 | 2022 | 72290 | 0.480 |
Why?
|
| Aged, 80 and over | 22 | 2021 | 57776 | 0.470 |
Why?
|
| Cohort Studies | 19 | 2020 | 40561 | 0.470 |
Why?
|
| Liver Failure | 1 | 2016 | 241 | 0.470 |
Why?
|
| DNA, Mitochondrial | 1 | 2018 | 817 | 0.460 |
Why?
|
| Wounds and Injuries | 2 | 2016 | 2400 | 0.450 |
Why?
|
| Patient Readmission | 5 | 2021 | 3114 | 0.430 |
Why?
|
| APACHE | 4 | 2017 | 277 | 0.430 |
Why?
|
| Acid-Base Equilibrium | 1 | 2013 | 185 | 0.420 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2017 | 612 | 0.410 |
Why?
|
| Craniotomy | 1 | 2016 | 729 | 0.410 |
Why?
|
| Humans | 83 | 2023 | 744343 | 0.410 |
Why?
|
| Erythrocyte Volume | 1 | 2011 | 30 | 0.410 |
Why?
|
| Residence Characteristics | 2 | 2012 | 2050 | 0.400 |
Why?
|
| Renal Replacement Therapy | 2 | 2018 | 257 | 0.400 |
Why?
|
| Severity of Illness Index | 4 | 2016 | 15540 | 0.390 |
Why?
|
| Retrospective Studies | 26 | 2022 | 77449 | 0.390 |
Why?
|
| Risk Assessment | 9 | 2021 | 23338 | 0.390 |
Why?
|
| Blood Urea Nitrogen | 1 | 2011 | 191 | 0.380 |
Why?
|
| Health Status Indicators | 2 | 2014 | 969 | 0.380 |
Why?
|
| Poverty Areas | 1 | 2012 | 275 | 0.370 |
Why?
|
| Energy Metabolism | 1 | 2021 | 2899 | 0.370 |
Why?
|
| Hyperkalemia | 1 | 2012 | 218 | 0.360 |
Why?
|
| Heart Transplantation | 6 | 2007 | 3110 | 0.350 |
Why?
|
| Cause of Death | 3 | 2021 | 3584 | 0.350 |
Why?
|
| Adult | 36 | 2023 | 214055 | 0.350 |
Why?
|
| Mortality | 2 | 2019 | 2864 | 0.340 |
Why?
|
| Gene Expression Profiling | 7 | 2004 | 9438 | 0.340 |
Why?
|
| Coronary Artery Bypass | 1 | 2018 | 2289 | 0.340 |
Why?
|
| Academic Medical Centers | 4 | 2017 | 2759 | 0.330 |
Why?
|
| Hospitals, Teaching | 4 | 2015 | 1179 | 0.330 |
Why?
|
| Discriminant Analysis | 2 | 2018 | 235 | 0.310 |
Why?
|
| Overweight | 2 | 2015 | 2371 | 0.300 |
Why?
|
| Endovascular Procedures | 1 | 2021 | 1979 | 0.300 |
Why?
|
| Clostridium Infections | 1 | 2014 | 548 | 0.290 |
Why?
|
| Bacteremia | 1 | 2013 | 962 | 0.280 |
Why?
|
| Burns | 1 | 2017 | 1815 | 0.270 |
Why?
|
| Multivariate Analysis | 6 | 2017 | 12245 | 0.260 |
Why?
|
| Creatinine | 1 | 2011 | 1919 | 0.260 |
Why?
|
| Time Factors | 9 | 2021 | 40075 | 0.250 |
Why?
|
| Cerebral Hemorrhage | 1 | 2016 | 2647 | 0.250 |
Why?
|
| Nutrition Therapy | 2 | 2016 | 96 | 0.250 |
Why?
|
| Graft Survival | 8 | 2022 | 3737 | 0.240 |
Why?
|
| Language | 1 | 2013 | 1471 | 0.240 |
Why?
|
| Magnesium Deficiency | 2 | 2020 | 47 | 0.230 |
Why?
|
| Sex Factors | 5 | 2021 | 10397 | 0.230 |
Why?
|
| Delirium | 1 | 2015 | 1609 | 0.230 |
Why?
|
| Magnesium | 3 | 2022 | 813 | 0.220 |
Why?
|
| Length of Stay | 4 | 2022 | 6309 | 0.220 |
Why?
|
| N-Formylmethionine | 1 | 2022 | 16 | 0.220 |
Why?
|
| Inflammation | 2 | 2021 | 10638 | 0.220 |
Why?
|
| Registries | 5 | 2021 | 8089 | 0.220 |
Why?
|
| Health Status | 1 | 2016 | 4034 | 0.220 |
Why?
|
| Obesity | 2 | 2015 | 12745 | 0.220 |
Why?
|
| Transplants | 2 | 2007 | 209 | 0.210 |
Why?
|
| Treatment Outcome | 12 | 2023 | 63114 | 0.210 |
Why?
|
| Kidney Transplantation | 3 | 2022 | 4251 | 0.210 |
Why?
|
| Endpoint Determination | 2 | 2015 | 601 | 0.200 |
Why?
|
| Major Histocompatibility Complex | 1 | 2004 | 936 | 0.200 |
Why?
|
| Confidence Intervals | 3 | 2011 | 2971 | 0.190 |
Why?
|
| Postoperative Complications | 3 | 2020 | 15295 | 0.190 |
Why?
|
| Body Mass Index | 2 | 2015 | 12720 | 0.190 |
Why?
|
| Plasmalogens | 1 | 2020 | 30 | 0.190 |
Why?
|
| Hand Strength | 1 | 2023 | 448 | 0.190 |
Why?
|
| Sphingomyelins | 1 | 2020 | 105 | 0.180 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 2022 | 251 | 0.180 |
Why?
|
| Selenium | 1 | 2023 | 405 | 0.180 |
Why?
|
| Deficiency Diseases | 1 | 2020 | 72 | 0.180 |
Why?
|
| Multigene Family | 2 | 2004 | 1102 | 0.180 |
Why?
|
| Age Factors | 5 | 2016 | 18370 | 0.170 |
Why?
|
| Propensity Score | 2 | 2016 | 1781 | 0.170 |
Why?
|
| Poverty | 1 | 2011 | 2660 | 0.170 |
Why?
|
| Placebos | 2 | 2020 | 1676 | 0.170 |
Why?
|
| Hyperuricemia | 1 | 2021 | 211 | 0.160 |
Why?
|
| Prognosis | 7 | 2020 | 29063 | 0.160 |
Why?
|
| Lysophospholipids | 1 | 2020 | 331 | 0.160 |
Why?
|
| Placebo Effect | 1 | 2021 | 502 | 0.150 |
Why?
|
| Multiple Organ Failure | 2 | 2022 | 390 | 0.150 |
Why?
|
| Mice, Inbred BALB C | 7 | 2007 | 6386 | 0.150 |
Why?
|
| Predictive Value of Tests | 4 | 2021 | 15076 | 0.150 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2021 | 783 | 0.150 |
Why?
|
| Wasting Syndrome | 1 | 2017 | 101 | 0.150 |
Why?
|
| Body Surface Area | 1 | 2017 | 198 | 0.140 |
Why?
|
| Hypoxanthine | 1 | 2016 | 28 | 0.140 |
Why?
|
| Preoperative Period | 1 | 2018 | 549 | 0.140 |
Why?
|
| Activities of Daily Living | 2 | 2023 | 2418 | 0.140 |
Why?
|
| Pyrrolidonecarboxylic Acid | 1 | 2016 | 65 | 0.140 |
Why?
|
| Proportional Hazards Models | 4 | 2021 | 12354 | 0.140 |
Why?
|
| Aftercare | 1 | 2022 | 866 | 0.140 |
Why?
|
| Kidney Function Tests | 2 | 2016 | 684 | 0.140 |
Why?
|
| Uric Acid | 1 | 2021 | 766 | 0.130 |
Why?
|
| Diabetes Mellitus | 2 | 2013 | 5751 | 0.130 |
Why?
|
| Double-Blind Method | 5 | 2023 | 12026 | 0.130 |
Why?
|
| Trauma Severity Indices | 1 | 2017 | 481 | 0.130 |
Why?
|
| Leukocyte Count | 1 | 2019 | 1588 | 0.130 |
Why?
|
| Dietary Supplements | 3 | 2020 | 3297 | 0.130 |
Why?
|
| Analysis of Variance | 4 | 2013 | 6365 | 0.130 |
Why?
|
| Nutrition Surveys | 3 | 2017 | 1660 | 0.130 |
Why?
|
| Glutamates | 1 | 2016 | 398 | 0.130 |
Why?
|
| Communicable Diseases | 1 | 2023 | 880 | 0.130 |
Why?
|
| Gastrointestinal Diseases | 1 | 2023 | 1170 | 0.120 |
Why?
|
| Fatty Acids | 1 | 2022 | 1809 | 0.120 |
Why?
|
| Colistin | 1 | 2014 | 47 | 0.120 |
Why?
|
| Survival Analysis | 5 | 2019 | 10252 | 0.120 |
Why?
|
| beta-Lactam Resistance | 1 | 2014 | 79 | 0.120 |
Why?
|
| Pulmonary Valve Insufficiency | 1 | 2015 | 151 | 0.120 |
Why?
|
| Peritonitis | 1 | 2016 | 365 | 0.120 |
Why?
|
| Glutathione | 1 | 2016 | 589 | 0.120 |
Why?
|
| Bone Remodeling | 1 | 2017 | 575 | 0.120 |
Why?
|
| Carbapenems | 1 | 2014 | 118 | 0.110 |
Why?
|
| Conflict of Interest | 1 | 2018 | 544 | 0.110 |
Why?
|
| Purines | 1 | 2016 | 594 | 0.110 |
Why?
|
| Inpatients | 2 | 2015 | 2518 | 0.110 |
Why?
|
| Survival Rate | 2 | 2018 | 12788 | 0.110 |
Why?
|
| Metabolic Diseases | 1 | 2019 | 658 | 0.110 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2014 | 232 | 0.110 |
Why?
|
| Follow-Up Studies | 5 | 2018 | 39050 | 0.110 |
Why?
|
| Influenza, Human | 1 | 2023 | 1479 | 0.100 |
Why?
|
| Physical Therapy Modalities | 1 | 2016 | 550 | 0.100 |
Why?
|
| Comorbidity | 2 | 2017 | 10388 | 0.100 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2022 | 1354 | 0.100 |
Why?
|
| Waiting Lists | 1 | 2016 | 692 | 0.100 |
Why?
|
| Endocarditis | 1 | 2015 | 350 | 0.100 |
Why?
|
| Thinness | 1 | 2015 | 480 | 0.100 |
Why?
|
| Blood Glucose | 2 | 2017 | 6256 | 0.100 |
Why?
|
| Preoperative Care | 1 | 2020 | 2250 | 0.100 |
Why?
|
| Renal Dialysis | 2 | 2016 | 1786 | 0.090 |
Why?
|
| Social Class | 2 | 2017 | 1999 | 0.090 |
Why?
|
| Gait | 1 | 2016 | 793 | 0.090 |
Why?
|
| Pneumonia, Bacterial | 1 | 2013 | 316 | 0.090 |
Why?
|
| Trauma Centers | 1 | 2016 | 890 | 0.090 |
Why?
|
| Myocardium | 1 | 2003 | 4776 | 0.090 |
Why?
|
| Sex Characteristics | 1 | 2021 | 2585 | 0.090 |
Why?
|
| Bone Density Conservation Agents | 1 | 2017 | 773 | 0.090 |
Why?
|
| Renal Insufficiency | 1 | 2016 | 804 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 3 | 2004 | 6171 | 0.090 |
Why?
|
| Surgery Department, Hospital | 1 | 2011 | 175 | 0.090 |
Why?
|
| Hospitals, University | 1 | 2011 | 571 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 7 | 2015 | 21827 | 0.080 |
Why?
|
| Clinical Trials as Topic | 2 | 2022 | 7913 | 0.080 |
Why?
|
| Reperfusion Injury | 1 | 2015 | 1026 | 0.080 |
Why?
|
| Patient Admission | 1 | 2016 | 1380 | 0.080 |
Why?
|
| Gene Expression Regulation | 3 | 2015 | 12072 | 0.080 |
Why?
|
| Transplantation, Homologous | 4 | 2004 | 4776 | 0.080 |
Why?
|
| Transcription, Genetic | 1 | 2002 | 7722 | 0.080 |
Why?
|
| Potassium | 1 | 2012 | 1336 | 0.080 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2014 | 783 | 0.080 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2023 | 3537 | 0.080 |
Why?
|
| Respiratory Tract Infections | 1 | 2015 | 961 | 0.080 |
Why?
|
| Bacterial Infections | 1 | 2016 | 1401 | 0.070 |
Why?
|
| Cytokines | 4 | 2004 | 7322 | 0.070 |
Why?
|
| Gene Deletion | 2 | 2004 | 2751 | 0.070 |
Why?
|
| Motor Activity | 1 | 2016 | 2714 | 0.070 |
Why?
|
| Recovery of Function | 1 | 2016 | 2925 | 0.070 |
Why?
|
| Endothelial Cells | 1 | 2018 | 3479 | 0.070 |
Why?
|
| Transplantation, Isogeneic | 2 | 2003 | 257 | 0.070 |
Why?
|
| Liver Cirrhosis | 1 | 2016 | 1863 | 0.070 |
Why?
|
| Forecasting | 1 | 2015 | 2951 | 0.070 |
Why?
|
| ROC Curve | 1 | 2013 | 3527 | 0.060 |
Why?
|
| General Surgery | 1 | 2016 | 1636 | 0.060 |
Why?
|
| Liver Transplantation | 1 | 2016 | 2119 | 0.060 |
Why?
|
| Genes, T-Cell Receptor | 1 | 2004 | 29 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2003 | 3920 | 0.060 |
Why?
|
| Qualitative Research | 1 | 2012 | 2682 | 0.060 |
Why?
|
| beta 2-Microglobulin | 1 | 2004 | 315 | 0.060 |
Why?
|
| Residual Volume | 1 | 2023 | 41 | 0.060 |
Why?
|
| Sodium Selenite | 1 | 2023 | 11 | 0.060 |
Why?
|
| Adolescent | 5 | 2020 | 85781 | 0.050 |
Why?
|
| Kidney Failure, Chronic | 1 | 2015 | 2538 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2004 | 342 | 0.050 |
Why?
|
| Transplantation Immunology | 1 | 2004 | 546 | 0.050 |
Why?
|
| Erythrocytes | 1 | 2011 | 2455 | 0.050 |
Why?
|
| CD40 Ligand | 1 | 2003 | 526 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2016 | 9146 | 0.050 |
Why?
|
| Animals | 11 | 2015 | 168757 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 9959 | 0.050 |
Why?
|
| Incidence | 2 | 2016 | 20947 | 0.050 |
Why?
|
| Mice | 9 | 2007 | 81183 | 0.050 |
Why?
|
| Prospective Studies | 3 | 2023 | 53288 | 0.050 |
Why?
|
| Public Health | 1 | 2013 | 2603 | 0.050 |
Why?
|
| Tetrahydrofolates | 1 | 2000 | 61 | 0.050 |
Why?
|
| Models, Statistical | 1 | 2015 | 5102 | 0.050 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2004 | 1475 | 0.040 |
Why?
|
| Sequence Deletion | 1 | 2004 | 1526 | 0.040 |
Why?
|
| Interleukins | 1 | 2004 | 791 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2013 | 3209 | 0.040 |
Why?
|
| Hyperhomocysteinemia | 1 | 2000 | 124 | 0.040 |
Why?
|
| Young Adult | 4 | 2020 | 56430 | 0.040 |
Why?
|
| Iatrogenic Disease | 1 | 2022 | 547 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2022 | 778 | 0.040 |
Why?
|
| Israel | 1 | 2021 | 796 | 0.040 |
Why?
|
| Stomach | 1 | 2023 | 697 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2012 | 7785 | 0.040 |
Why?
|
| Models, Animal | 1 | 2004 | 2171 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2007 | 3200 | 0.040 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2019 | 370 | 0.040 |
Why?
|
| Micronutrients | 1 | 2020 | 375 | 0.040 |
Why?
|
| Mice, Knockout | 4 | 2004 | 14557 | 0.040 |
Why?
|
| Osteocalcin | 1 | 2017 | 273 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 19905 | 0.040 |
Why?
|
| United States | 4 | 2018 | 69872 | 0.040 |
Why?
|
| Phosphates | 1 | 2020 | 786 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2014 | 7181 | 0.030 |
Why?
|
| Cell Communication | 1 | 2003 | 1621 | 0.030 |
Why?
|
| Antigens, CD | 2 | 2004 | 4026 | 0.030 |
Why?
|
| Heart Failure | 1 | 2018 | 10900 | 0.030 |
Why?
|
| Kinetics | 1 | 2002 | 6473 | 0.030 |
Why?
|
| Calcifediol | 1 | 2015 | 166 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2003 | 4217 | 0.030 |
Why?
|
| Calcitriol | 1 | 2015 | 298 | 0.030 |
Why?
|
| Folic Acid | 1 | 2000 | 1300 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2023 | 1790 | 0.030 |
Why?
|
| Receptors, Nerve Growth Factor | 2 | 2004 | 200 | 0.030 |
Why?
|
| Independent Living | 1 | 2017 | 568 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 2003 | 3768 | 0.030 |
Why?
|
| Pulmonary Alveoli | 1 | 2015 | 675 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2003 | 3474 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2003 | 4420 | 0.030 |
Why?
|
| Graft vs Host Disease | 1 | 2004 | 2957 | 0.030 |
Why?
|
| Energy Intake | 1 | 2019 | 2148 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2004 | 9734 | 0.020 |
Why?
|
| Mice, Inbred Strains | 2 | 2004 | 1827 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor | 2 | 2004 | 595 | 0.020 |
Why?
|
| Linear Models | 1 | 2021 | 5952 | 0.020 |
Why?
|
| Esophagectomy | 1 | 2015 | 447 | 0.020 |
Why?
|
| History, 21st Century | 1 | 2017 | 1534 | 0.020 |
Why?
|
| Kidney Diseases | 1 | 2021 | 2149 | 0.020 |
Why?
|
| Consensus | 1 | 2019 | 2959 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2002 | 2958 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2022 | 4149 | 0.020 |
Why?
|
| Collagen | 1 | 2017 | 2689 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2016 | 2170 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2004 | 10180 | 0.020 |
Why?
|
| Research Design | 1 | 2022 | 5987 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2004 | 3870 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2004 | 5442 | 0.020 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2007 | 310 | 0.020 |
Why?
|
| Interferon-gamma | 2 | 2003 | 3206 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2017 | 25043 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2017 | 5097 | 0.020 |
Why?
|
| Glucocorticoid-Induced TNFR-Related Protein | 1 | 2004 | 42 | 0.020 |
Why?
|
| Bone Density | 1 | 2017 | 3468 | 0.020 |
Why?
|
| STAT4 Transcription Factor | 1 | 2003 | 96 | 0.010 |
Why?
|
| 4-1BB Ligand | 1 | 2003 | 29 | 0.010 |
Why?
|
| Genes, RAG-1 | 1 | 2003 | 68 | 0.010 |
Why?
|
| STAT6 Transcription Factor | 1 | 2003 | 199 | 0.010 |
Why?
|
| Algorithms | 1 | 2004 | 13881 | 0.010 |
Why?
|
| Lymphocyte Transfusion | 1 | 2004 | 236 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 3610 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2015 | 3690 | 0.010 |
Why?
|
| Ribonuclease, Pancreatic | 1 | 2003 | 154 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2007 | 4479 | 0.010 |
Why?
|
| Disease Models, Animal | 2 | 2015 | 18029 | 0.010 |
Why?
|
| Antigens, Differentiation | 1 | 2004 | 927 | 0.010 |
Why?
|
| Disease Progression | 1 | 2017 | 13284 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 2013 | 3966 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2003 | 1799 | 0.010 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2013 | 2208 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2015 | 19229 | 0.010 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2013 | 3047 | 0.010 |
Why?
|
| Th1 Cells | 1 | 2003 | 1057 | 0.010 |
Why?
|
| Th2 Cells | 1 | 2003 | 1061 | 0.010 |
Why?
|
| Prevalence | 1 | 2015 | 15226 | 0.010 |
Why?
|
| Spleen | 1 | 2004 | 2362 | 0.010 |
Why?
|
| Forkhead Transcription Factors | 1 | 2004 | 1613 | 0.010 |
Why?
|
| Homocysteine | 1 | 2000 | 647 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2004 | 2715 | 0.010 |
Why?
|
| DNA-Binding Proteins | 2 | 2004 | 9648 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2004 | 2007 | 0.010 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2004 | 1838 | 0.010 |
Why?
|
| Asthma | 1 | 2013 | 6011 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2007 | 4386 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2000 | 2618 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2003 | 2924 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2000 | 3913 | 0.010 |
Why?
|
| Child | 1 | 2020 | 77709 | 0.010 |
Why?
|
| Gene Expression | 1 | 2004 | 7799 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 11366 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2000 | 10943 | 0.000 |
Why?
|
| Cardiovascular Diseases | 1 | 2013 | 15165 | 0.000 |
Why?
|